Refining detection of drug-induced proarrhythmia: QT interval and TRIaD.

QT interval prolongation is so frequently associated with torsades de pointes (TdP) that it has come to be recognized as a surrogate marker of this unique tachyarrhythmia. However, not only does TdP not always follow QT interval prolongation, but TdP can occur even in the absence of a prolonged QT interval. Worse still, even shortening of the QT interval may be associated with serious arrhythmias (particularly ventricular tachycardia [VT] and ventricular fibrillation [VF]). It appears increasingly probable that the distinction between various ventricular tachyarrhythmias may be arbitrary, and drug-induced TdP, polymorphic VT, VT, catecholaminergic polymorphic VT, and VF may represent discrete entities within a spectrum of drug-induced proarrhythmia. Although they are differentiated by the coupling interval and the duration of QT interval, they appear to share a common substrate: a set of disturbances of repolarization characterized by Triangulation, Reverse use dependency, electrical Instability of the action potential, and Dispersion (TRIaD). It is becoming increasingly evident that augmentation of TRIaD, rather than changes in the duration of QT interval, provides the proarrhythmic substrate. In contrast, when not associated with an increase of TRIaD, QT interval prolongation can be an antiarrhythmic property. Electrophysiologically, augmentation of TRIaD can be explained by inhibition of hERG (human ether-a-go-go related gene) channel. Because drug-induced disturbances in repolarization commonly result from inhibition of hERG channels or I(Kr), hERG blockade and the resulting prolongation of QT interval are important properties of a drug to be studied. However, these need only be a concern if associated with TRIaD. More significantly, TRIaD so often precedes prolongation of action potential duration or QT interval and ventricular tachyarrhythmias that it should be considered a marker of proarrhythmia until proven otherwise, even in the absence of QT interval prolongation. Detecting drug-induced augmentation of TRIaD may offer an additional, more sensitive, and accurate indicator of the broader proarrhythmic potential of a drug than may QT interval prolongation alone.

[1]  Marek Malik,et al.  Practical use of T wave morphology assessment. , 2002, Cardiac electrophysiology review.

[2]  L. Demay,et al.  Notched T Waves on Holter Recordings Enhance Detection of Patients With LQT2 (HERG) Mutations , 2001, Circulation.

[3]  F. Charpentier,et al.  Effects of chronic treatment by amiodarone on transmural heterogeneity of canine ventricular repolarization in vivo: interactions with acute sotalol. , 1999, Cardiovascular research.

[4]  Jean-Pierre Valentin,et al.  Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. , 2004, Journal of pharmacological and toxicological methods.

[5]  N. El-Sherif,et al.  TU Alternans, Long QTU, and Torsade de Pointes: Clinical and Experimental Observations , 1992 .

[6]  A Garfinkel,et al.  Patterns of wave break during ventricular fibrillation in isolated swine right ventricle. , 2001, American journal of physiology. Heart and circulatory physiology.

[7]  B. Singh,et al.  Control of cardiac arrhythmias by lengthening repolarization , 1988 .

[8]  T. Ohe,et al.  Torsade de pointes with a normal QT interval associated with hypokalemia: a case report. , 2001, Japanese circulation journal.

[9]  M. Radford,et al.  Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. CHF-STAT Investigators. , 1996, Circulation.

[10]  Jules C Hancox,et al.  Inhibitory actions of the selective serotonin re‐uptake inhibitor citalopram on HERG and ventricular L‐type calcium currents , 2002, FEBS letters.

[11]  Marc A. Vos,et al.  Electrophysiological Safety of Sertindole in Dogs with Normal and Remodeled Hearts , 2003, Journal of Pharmacology and Experimental Therapeutics.

[12]  D. Wysowski,et al.  Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and food and drug administration regulatory actions , 2001, American Journal of Gastroenterology.

[13]  D. Zipes,et al.  Alpha-adrenoceptor stimulation and blockade modulates cesium-induced early afterdepolarizations and ventricular tachyarrhythmias in dogs. , 1990, Circulation.

[14]  Y. Aizawa,et al.  Role of α1-Blockade in Congenital Long QT Syndrome , 2001 .

[15]  L. Hondeghem TRIad: foundation for proarrhythmia (triangulation, reverse use dependence and instability). , 2005, Novartis Foundation symposium.

[16]  J. Morganroth Relations of QTc prolongation on the electrocardiogram to torsades de pointes: definitions and mechanisms. , 1993, The American journal of cardiology.

[17]  Charles Antzelevitch,et al.  Assessing predictors of drug-induced torsade de pointes. , 2003, Trends in pharmacological sciences.

[18]  Charles Antzelevitch,et al.  Amplified Transmural Dispersion of Repolarization as the Basis for Arrhythmogenesis in a Canine Ventricular-Wedge Model of Short-QT Syndrome , 2004, Circulation.

[19]  Jiesheng Kang,et al.  Cardiac Ion Channel Effects of Tolterodine , 2004, Journal of Pharmacology and Experimental Therapeutics.

[20]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[21]  A. Moss T-wave patterns associated with the hereditary long QT syndrome. , 2002, Cardiac electrophysiology review.

[22]  J. Daubert,et al.  Les torsades de pointe: A propos de 54 cas , 1982 .

[23]  A. Camm,et al.  Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. , 2003, Cardiovascular research.

[24]  J. Brachmann,et al.  Electrocardiographic and Clinical Predictors of Torsades de Pointes Induced by Almokalant Infusion in Patients with Chronic Atrial Fibrillation or Flutter: A Prospective Study , 1998, Pacing and clinical electrophysiology : PACE.

[25]  S. Connolly,et al.  Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT , 1997, The Lancet.

[26]  H. Morita,et al.  Nicorandil abolished repolarisation alternans in a patient with idiopathic long QT syndrome , 1999, Heart.

[27]  K. Kugiyama,et al.  Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. , 2002, Circulation journal : official journal of the Japanese Circulation Society.

[28]  G. Kay,et al.  Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. , 1983, Journal of the American College of Cardiology.

[29]  M. Lesch,et al.  Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy. , 1989, Annals of internal medicine.

[30]  J. M. Di Diego,et al.  Cisapride-Induced Transmural Dispersion of Repolarization and Torsade de Pointes in the Canine Left Ventricular Wedge Preparation During Epicardial Stimulation , 2003, Circulation.

[31]  A. Moss,et al.  ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. , 1995, Circulation.

[32]  P. Coumel,et al.  Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. , 1995, Circulation.

[33]  M. Nagashima,et al.  Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death , 2003, Heart.

[34]  G. Gintant,et al.  The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis , 2001, Journal of cardiovascular pharmacology.

[35]  R. Brugada,et al.  Further Insights into the Effect of Quinidine in Short QT Syndrome Caused by a Mutation in HERG , 2005, Journal of cardiovascular electrophysiology.

[36]  Effect of Phenylephrine Provocation on Dispersion of Repolarization in Congenital Long QT Syndrome , 2003, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[37]  S. Hohnloser,et al.  Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia , 1994, Annals of Internal Medicine.

[38]  B. Grubb The use of oral labetalol in the treatment of arrhythmias associated with the long QT syndrome. , 1991, Chest.

[39]  S. Priori,et al.  A Novel Form of Short QT Syndrome (SQT3) Is Caused by a Mutation in the KCNJ2 Gene , 2005, Circulation research.

[40]  Hua-rong Lu,et al.  Detection of Proarrhythmia in the Female Rabbit Heart: , 2003, Journal of cardiovascular electrophysiology.

[41]  D. Raunig,et al.  The Relationship of Clinical QT Prolongation to Outcome in the Conscious Dog Using a Beat-to-Beat QT-RR Interval Assessment , 2002, Journal of Pharmacology and Experimental Therapeutics.

[42]  I Kodama,et al.  Open channel block of HERG K(+) channels by vesnarinone. , 2001, Molecular pharmacology.

[43]  Suppression of Torsades de Pointes with verapamil in patients with atrio-ventricular block. , 1991, European heart journal.

[44]  C Antzelevitch,et al.  Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. , 1998, Circulation.

[45]  Gary A Gintant,et al.  The Utility of hERG and Repolarization Assays in Evaluating Delayed Cardiac Repolarization: Influence of Multi-Channel Block , 2004, Journal of cardiovascular pharmacology.

[46]  N. Hasebe,et al.  A Case of a Short‐Coupled Variant of Torsades De Pointes with Electrical Storm , 2003, Pacing and clinical electrophysiology : PACE.

[47]  Todd Wisialowski,et al.  Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig. , 2004, European journal of pharmacology.

[48]  J. Morganroth Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias. , 1987, The American journal of cardiology.

[49]  J. Brugada,et al.  Idiopathic Short QT Interval:A New Clinical Syndrome? , 2001, Cardiology.

[50]  M. Scheinman,et al.  Polymorphous ventricular tachycardia: clinical characterization, therapy, and the QT interval. , 1986, Circulation.

[51]  A. Moss,et al.  T wave alternans in idiopathic long QT syndrome. , 1994, Journal of the American College of Cardiology.

[52]  P. Denes,et al.  Clinical, electrocardiographic and follow-up observations in patients having ventricular fibrillation during Holter monitoring. Role of quinidine therapy. , 1981, The American journal of cardiology.

[53]  D J Triggle,et al.  Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. , 2001, Molecular pharmacology.

[54]  D. Roden Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.

[55]  T. Colatsky,et al.  What happens when cardiac Na channel function is compromised? 2. Numerical studies of the vulnerable period in tissue altered by drugs. , 2003, Cardiovascular research.

[56]  M R Franz,et al.  Sudden cardiac death and polymorphous ventricular tachycardia in patients with normal QT intervals and normal systolic cardiac function. , 1995, The American journal of cardiology.

[57]  W. Shen,et al.  Catecholamine-induced T-wave lability in congenital long QT syndrome: a novel phenomenon associated with syncope and cardiac arrest. , 2003, Mayo Clinic proceedings.

[58]  Gea-Ny Tseng,et al.  IKr: The hERG Channel , 2001 .

[59]  M R Franz,et al.  Bridging the Gap Between Basic and Clinical Electrophysiology: , 1994, Journal of cardiovascular electrophysiology.

[60]  S. Priori,et al.  Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome. , 2002, Journal of the American College of Cardiology.

[61]  Wataru Shimizu,et al.  Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome. , 2004 .

[62]  A. Camm,et al.  Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? , 1998, The American journal of cardiology.

[63]  C. Obejero-Paz,et al.  Mechanisms of arsenic-induced prolongation of cardiac repolarization. , 2004, Molecular pharmacology.

[64]  I Kodama,et al.  Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes. , 1999, European journal of pharmacology.

[65]  N. Urao,et al.  Idiopathic long QT syndrome with early afterdepolarization induced by epinephrine. Acase report. , 2004, Circulation journal : official journal of the Japanese Circulation Society.

[66]  C. Antzelevitch,et al.  Effects of Sodium Channel Block with Mexiletine to Reverse Action Potential Prolongation in In Vitro Models of the Long QT Syndrome , 1997, Journal of cardiovascular electrophysiology.

[67]  P. Coumel,et al.  Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. , 1994, Circulation.

[68]  T. Meinertz Mibefradil : a drug which may enhance the propensity for the development of abnormal QT prolongation , 2001 .

[69]  P. Sager,et al.  Frequency-dependent electrophysiologic effects of amiodarone in humans. , 1993, Circulation.

[70]  S. Priori,et al.  Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. , 2001, Journal of the American College of Cardiology.

[71]  G. Breithardt,et al.  Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. , 2002, The Journal of pharmacology and experimental therapeutics.

[72]  G. Breithardt,et al.  Clinical aspects of ventricular arrhythmias associated with QT prolongation , 2001 .

[73]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[74]  W. Brady,et al.  Prevalence, therapeutic response, and outcome of ventricular tachycardia in the out-of-hospital setting: a comparison of monomorphic ventricular tachycardia, polymorphic ventricular tachycardia, and torsades de pointes. , 1999, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[75]  Y. Ruan,et al.  Short-coupled variant of torsade de pointes. , 2001, Journal of Tongji Medical University = Tong ji yi ke da xue xue bao.

[76]  M. Iliou,et al.  [Torsades de pointes]. , 1993, Archives des maladies du coeur et des vaisseaux.

[77]  H. Kennedy,et al.  Torsades de pointes associated with drugs and toxins: recognition and management. , 1987, American heart journal.

[78]  Torsade de Pointes , 2003 .

[79]  A. Camm,et al.  Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. , 1999, The New England journal of medicine.

[80]  R. Lazzara,et al.  Early Afterdepolarizations Produced by d,1‐Sotalol and Clofilium , 1997, Journal of cardiovascular electrophysiology.

[81]  A. Moss,et al.  Primidone in the treatment of the long QT syndrome: QT shortening and ventricular arrhythmia suppression. , 1980, Annals of internal medicine.

[82]  Yoshihisa Kurachi,et al.  [Evaluation of pro-arrhythmic risk of drugs due to QT interval prolongation by the HERG expression system]. , 2002, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

[83]  N. White,et al.  Quinine and Quinidine: A Comparison of EKG Effects During the Treatment of Malaria , 1983, Journal of cardiovascular pharmacology.

[84]  B. Surawicz Torsades de pointes: unanswered questions. , 2002, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[85]  D. Roden,et al.  Drug Block of I Kr : Model Systems and Relevance to Human Arrhythmias , 2001, Journal of cardiovascular pharmacology.

[86]  CHARLES ANTZELEVITCH,et al.  The M Cell: , 1999, Journal of cardiovascular electrophysiology.

[87]  M. Franz,et al.  Electrophysiological basis of QT dispersion measurements. , 2000, Progress in cardiovascular diseases.

[88]  Akihiko Kandori,et al.  Reconstruction of action potential of repolarization in patients with congenital long-QT syndrome. , 2004, Physics in medicine and biology.

[89]  R. Lux,et al.  T-wave alternans in LQTS: repolarization-rate dynamics from digital 12-lead Holter data. , 2001, Journal of electrocardiology.

[90]  P. Hoffmann,et al.  Blinded Test in Isolated Female Rabbit Heart Reliably Identifies Action Potential Duration Prolongation and Proarrhythmic Drugs: Importance of Triangulation, Reverse Use Dependence, and Instability , 2003, Journal of cardiovascular pharmacology.

[91]  A. Camm,et al.  Mortality in Patients After a Recent Myocardial Infarction: A Randomized, Placebo-Controlled Trial of Azimilide Using Heart Rate Variability for Risk Stratification , 2004, Circulation.

[92]  P. Nihoyannopoulos,et al.  Echocardiographic pitfalls in the diagnosis of hypertrophic cardiomyopathy , 1999, Heart.

[93]  W. Shimizu,et al.  Exercise Stress Test Amplifies Genotype-Phenotype Correlation in the LQT1 and LQT2 Forms of the Long-QT Syndrome , 2003, Circulation.

[94]  Milan Stengl,et al.  Increased Short-Term Variability of Repolarization Predicts d-Sotalol–Induced Torsades de Pointes in Dogs , 2004, Circulation.

[95]  E. Prystowsky,et al.  Clinical characteristics of patients with ventricular fibrillation during antiarrhythmic drug therapy. , 1988, The New England journal of medicine.

[96]  J. M. Di Diego,et al.  Electrophysiologic Properties and Antiarrhythmic Actions of a Novel Antianginal Agent , 2004, Journal of cardiovascular pharmacology and therapeutics.

[97]  T. Tomson,et al.  Phenytoin and phenobarbital inhibit human HERG potassium channels , 2003, Epilepsy Research.

[98]  A. Katchman,et al.  The antiestrogen tamoxifen blocks the delayed rectifier potassium current, IKr, in rabbit ventricular myocytes. , 1998, The Journal of pharmacology and experimental therapeutics.

[99]  P. Kowey,et al.  Electrophysiologic Effects of SB-237376: A New Antiarrhythmic Compound with Dual Potassium and Calcium Channel Blocking Action , 2003, Journal of cardiovascular pharmacology.

[100]  Dierk Thomas,et al.  The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. , 2002, The Journal of pharmacology and experimental therapeutics.

[101]  P Maison-Blanche,et al.  Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation. , 1997, Journal of the American College of Cardiology.

[102]  Craig T. January,et al.  Early Afterdepolarizations: Mechanism of Induction and Block A Role for L‐Type Ca2+ Current , 1989, Circulation research.

[103]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[104]  C. Antzelevitch,et al.  Cellular and ionic basis for T-wave alternans under long-QT conditions. , 1999, Circulation.

[105]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[106]  R. Califf,et al.  Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. , 2002, American heart journal.

[107]  G. Breithardt,et al.  Divergent Proarrhythmic Potential of Macrolide Antibiotics Despite Similar QT Prolongation: Fast Phase 3 Repolarization Prevents Early Afterdepolarizations and Torsade de Pointes , 2002, Journal of Pharmacology and Experimental Therapeutics.

[108]  T J Campbell,et al.  Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate , 1999, British journal of pharmacology.

[109]  A. Garfinkel,et al.  Chaos and the transition to ventricular fibrillation: a new approach to antiarrhythmic drug evaluation. , 1999, Circulation.

[110]  Wojciech Zareba,et al.  Repolarization Dynamics in Patients with Long QT Syndrome , 2002, Journal of cardiovascular electrophysiology.

[111]  P. Kowey,et al.  Phase 2 Early Afterdepolarization as a Trigger of Polymorphic Ventricular Tachycardia in Acquired Long-QT Syndrome: Direct Evidence From Intracellular Recordings in the Intact Left Ventricular Wall , 2001, Circulation.

[112]  A. V. van Ginneken,et al.  Mutation in the KCNQ1 Gene Leading to the Short QT-Interval Syndrome , 2004, Circulation.

[113]  M. Zaniboni,et al.  Beat-to-beat repolarization variability in ventricular myocytes and its suppression by electrical coupling. , 2000, American journal of physiology. Heart and circulatory physiology.

[114]  H. Huikuri Dispersion of Repolarisation and the Autonomic System—Can We Predict Torsade de Pointes? , 2002, Cardiovascular Drugs and Therapy.

[115]  C. Antzelevitch,et al.  Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. , 2000, Circulation.

[116]  B. Katzung,et al.  Effects of Extracellular Potassium on Ventricular Automaticity and Evidence for a Pacemaker Current in Mammalian Ventricular Myocardium , 1977, Circulation research.

[117]  A. Camm,et al.  Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT , 1997, The Lancet.

[118]  Martin Borggrefe,et al.  Congenital Short QT Syndrome and Implantable Cardioverter Defibrillator Treatment: , 2003, Journal of cardiovascular electrophysiology.

[119]  M. Shoda,et al.  Electrophysiological characteristic of a patient exhibiting the short-coupled variant of torsade de pointes. , 2001, Journal of electrocardiology.

[120]  Y. Aizawa,et al.  Nicorandil suppresses a hump on the monophasic action potential and torsade de pointes in a patient with idiopathic long QT syndrome. , 1995, Japanese heart journal.

[121]  R. Zimlichman,et al.  Polymorphous ventricular tachycardia. , 1983, The American journal of cardiology.

[122]  M. Janse,et al.  Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials , 1997, The Lancet.

[123]  Shien-Fong Lin,et al.  Spatial heterogeneity of action potential alternans during global ischemia in the rabbit heart. , 2003, American journal of physiology. Heart and circulatory physiology.

[124]  M. Messier,et al.  Predictive Factors of Ventricular Fibrillation Triggered by Pause‐Dependent Torsades de Pointes Associated with Acquired Long QT Interval: , 2000, Journal of cardiovascular electrophysiology.

[125]  H. Morita,et al.  Nicorandil attenuates both temporal and spatial repolarization alternans. , 2000, Journal of electrocardiology.

[126]  Hua-rong Lu,et al.  Drug-induced long QT in isolated rabbit Purkinje fibers: importance of action potential duration, triangulation and early afterdepolarizations. , 2002, European journal of pharmacology.

[127]  Lauri Toivonen,et al.  Ambulatory Electrocardiographic Evidence of Transmural Dispersion of Repolarization in Patients With Long-QT Syndrome Type 1 and 2 , 2002, Circulation.

[128]  W. Shen,et al.  Catecholamine‐Provoked Microvoltage T Wave Alternans in Genotyped Long QT Syndrome , 2003, Pacing and clinical electrophysiology : PACE.

[129]  L. Gettes,et al.  T Wave Alternans and Torsades de Pointes After the Use of Intravenous Pentamidine , 2002, Journal of cardiovascular electrophysiology.

[130]  B. Katzung,et al.  Cardiac ventricular automaticity induced by current of injury , 1975, Pflügers Archiv European Journal of Physiology.

[131]  Bente Brendorp,et al.  A Benefit-Risk Assessment of Class III Antiarrhythmic Agents , 2002, Drug safety.

[132]  S. Swiryn,et al.  Familial inducible torsade de pointes with normal QT interval. , 1983, European heart journal.

[133]  K. Sunagawa,et al.  Excessive Increase in QT Interval and Dispersion of Repolarization Predict Recurrent Ventricular Tachyarrhythmia after Amiodarone , 2004, Pacing and clinical electrophysiology : PACE.

[134]  H. Doval,et al.  Randomised trial of low-dose amiodarone in severe congestive heart failure , 1994, The Lancet.

[135]  B. Fermini,et al.  The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.

[136]  P. Puech,et al.  Torsades de Pointe , 1988 .

[137]  A. Bénardeau,et al.  Effects of the T-type Ca(2+) channel blocker mibefradil on repolarization of guinea pig, rabbit, dog, monkey, and human cardiac tissue. , 2000, The Journal of pharmacology and experimental therapeutics.

[138]  Martin Borggrefe,et al.  Short QT Syndrome: A Familial Cause of Sudden Death , 2003, Circulation.

[139]  S. Olsson,et al.  Monophasic Action Potentials: , 1994, Journal of cardiovascular electrophysiology.

[140]  C. Antzelevitch,et al.  Antiarrhythmic Effects of Ranolazine in a Guinea Pig in Vitro Model of Long-QT Syndrome , 2004, Journal of Pharmacology and Experimental Therapeutics.

[141]  R. Shah,et al.  Pharmacogenetic Aspects of Drug-Induced Torsade de Pointes , 2004, Drug safety.

[142]  A. Camm,et al.  Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators. , 1999, Circulation.

[143]  M. Rosen,et al.  Chronic in vivo and in vitro effects of amiodarone on guinea pig hearts. , 1996, The Journal of pharmacology and experimental therapeutics.

[144]  J. Mason,et al.  Risk Factors for Tachycardia Events Caused by Antiarrhythmic Drugs: Experience From the ESVEM Trial , 1998, Journal of cardiovascular pharmacology and therapeutics.

[145]  C. January,et al.  Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.

[146]  Wataru Shimizu,et al.  Cellular mechanisms underlying the long QT syndrome. , 2002, Current opinion in cardiology.

[147]  C R Benedict,et al.  Interactions of the 5-hydroxytryptamine 3 antagonist class of antiemetic drugs with human cardiac ion channels. , 2000, The Journal of pharmacology and experimental therapeutics.

[148]  J. Brugada,et al.  Sudden Death Associated With Short-QT Syndrome Linked to Mutations in HERG , 2003, Circulation.

[149]  G. Duker,et al.  Instability and Triangulation of the Action Potential Predict Serious Proarrhythmia, but Action Potential Duration Prolongation Is Antiarrhythmic , 2001, Circulation.

[150]  D. Snyders,et al.  Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. , 1990, Circulation.

[151]  S. O’Donoghue,et al.  Levofloxacin Induced Polymorphic Ventricular Tachycardia with Normal QT Interval , 2001, Pacing and clinical electrophysiology : PACE.

[152]  P. Kowey,et al.  Ventricular fibrillation during coronary angiography: the precatheterization QT interval. , 1987, Journal of electrocardiology.

[153]  J. Rey,et al.  [Torsades de pointe. Apropos of 60 cases]. , 1985, Annales de cardiologie et d'angeiologie.

[154]  A. Camm,et al.  Effect of amiodarone on the descending limb of the T wave. , 2003, The American journal of cardiology.

[155]  L. Makarov,et al.  [QT interval shortening in families with history of sudden death at young age]. , 2004, Kardiologiia.

[156]  S. Hohnloser,et al.  Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study. , 2001, Journal of the American College of Cardiology.

[157]  A J Moss,et al.  ECG features of microvolt T-wave alternans in coronary artery disease and long QT syndrome patients. , 1998, Journal of electrocardiology.

[158]  Bramahn . Singh,et al.  Antiarrhythmic and Proarrhythmic Properties of QT-Prolonging Antianginal Drugs , 2004, Journal of cardiovascular pharmacology and therapeutics.

[159]  C Antzelevitch,et al.  Cellular basis for QT dispersion. , 1998, Journal of electrocardiology.

[160]  R. Lazzara Amiodarone and torsade de pointes. , 1989, Annals of internal medicine.

[161]  A. Keren,et al.  Etiology, Warning Signs and Therapy of Torsade de Pointes: A Study of 10 Patients , 1981, Circulation.

[162]  C. Antzelevitch,et al.  Unique Topographical Distribution of M Cells Underlies Reentrant Mechanism of Torsade de Pointes in the Long-QT Syndrome , 2002, Circulation.

[163]  L. Hondeghem,et al.  Phase 2 prolongation, in the absence of instability and triangulation, antagonizes class III proarrhythmia. , 2001, Cardiovascular research.

[164]  C. White,et al.  Amiodarone in the New AHA Guidelines for Ventricular Tachyarrhythmias , 2001, The Annals of pharmacotherapy.

[165]  Y. Kuryshev,et al.  Pentamidine-Induced Long QT Syndrome and Block of hERG Trafficking , 2005, Journal of Pharmacology and Experimental Therapeutics.

[166]  M. Scheinman,et al.  Evaluation and management of patients with polymorphic ventricular tachycardia. , 1993, Cardiology clinics.

[167]  E. Williams Classification of Antiarrhythmic Actions , 1989 .

[168]  T. Fraker,et al.  Polymorphous ventricular tachycardia provoked by lidocaine. , 1985, The American journal of cardiology.

[169]  S. Swiryn,et al.  Torsade de pointes due to quinidine: observations in 31 patients. , 1984, American heart journal.

[170]  N. Yoshimoto,et al.  Nicorandil, a Potassium Channel Opener, Abolished Torsades de Pointes in a Patient with Complete Atrioventricular Block , 1999, Pacing and clinical electrophysiology : PACE.

[171]  H. Morita,et al.  Early Afterdepolarization Abolished by Potassium Channel Opener in a Patient with Idiopathic Long QT Syndrome , 1995, Journal of cardiovascular electrophysiology.

[172]  R. Shah,et al.  The significance of QT interval in drug development. , 2002, British journal of clinical pharmacology.

[173]  E. Zitron,et al.  Rapid component I(Kr) of the guinea-pig cardiac delayed rectifier K(+) current is inhibited by beta(1)-adrenoreceptor activation, via cAMP/protein kinase A-dependent pathways. , 2002, Cardiovascular research.